Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Bryan H. Simpson"'
Publikováno v:
Journal of Primary Health Care, Vol 12, Iss 4, Pp 327-334 (2020)
ABSTRACT INTRODUCTIONDabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking. AIMTo investigate if clinically appropriate renal function monitoring is being
Externí odkaz:
https://doaj.org/article/13a61cca7271446fb7d8bfde50b40439
Publikováno v:
TH Open, Vol 03, Iss 03, Pp e210-e215 (2019)
Abstract Background Dabigatran etexilate has become widely used for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). Currently, there is limited information in real-world patients relating to dabigatran etexilate ex
Externí odkaz:
https://doaj.org/article/9fae1b536eac4845a8091b5dd27cb35f
Publikováno v:
TH Open, Vol 02, Iss 04, Pp e420-e427 (2018)
Abstract Background Clinical significance of dosing dabigatran with different estimates of renal function for treatment of atrial fibrillation (AF) is unknown. Renal function is routinely estimated by the chronic kidney disease epidemiology initiat
Externí odkaz:
https://doaj.org/article/6d784366612745f491ff0d8f327a63a5
Publikováno v:
TH Open, Vol 03, Iss 03, Pp e210-e215 (2019)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Background Dabigatran etexilate has become widely used for the prevention of stroke in patients with nonvalvular atrial fibrillation (NVAF). Currently, there is limited information in real-world patients relating to dabigatran etexilate exposure and
Publikováno v:
Journal of primary health care. 10(4)
ABSTRACT INTRODUCTION Dabigatran etexilate is now prescribed for 51% of the patients receiving oral anticoagulation treatment in New Zealand. Its prescribing trends in relation to patient outcomes are, however, largely unknown for these patients. AIM
Publikováno v:
Journal of Primary Health Care, Vol 12, Iss 4, Pp 327-334 (2020)
ABSTRACT INTRODUCTIONDabigatran etexilate has become widely used in New Zealand, but information relating to when renal function monitoring is being undertaken is lacking. AIMTo investigate if clinically appropriate renal function monitoring is being
Publikováno v:
Clinical Therapeutics. 39:e7
Publikováno v:
Clinical Therapeutics. 39:e7
Publikováno v:
Clinical Therapeutics. 39:e8
Publikováno v:
Archives of Disease in Childhood. 101:e1.18-e1
BackgroundThe New Zealand Formulary for Children (NZFc) was developed to build on the New Zealand Universal List of Medicines through the addition of clinical information about medicines use in paediatrics. The structure and content of the NZFc is ba